News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
InCarda Initiates Enrollment Of Phase 1 Clinical Trial Of Inhaled Flecainide For The Treatment Of Cardiac Arrhythmias 8/31/2016
Asterias Biotherapeutics Receives Safety Clearance To Begin Administering The Highest Dose Of AST-OPC1 In The SCiStar Phase 1/2a Clinical Trial In Cervical Spinal Cord Injury Patients 8/31/2016
Neurimmune Therapeutics Release: Early Results Show Aducanumab Removes Amyloid Plaques In Patients With Alzheimer’s Disease 8/31/2016
Oncternal Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Of TK216 In Ewing Sarcoma 8/30/2016
Syros Pharma’s Scientific Founders Publish On First Selective CDK12 And CDK13 Inhibitor As Promising Approach For Treatment Of Cancer 8/30/2016
Gradalis Inc. Announces Dosing Of First Patient In Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy And Durvalumab In Advanced Breast Cancer 8/29/2016
Abeona Therapeutics Completes Enrollment Of Low-Dose Cohort For ABO-102 In Phase 1/2 Clinical Trial For MPS IIIA Patients 8/29/2016
BirchBioMed Announces Completion Of Clinical Trial For Ground-Breaking Anti-Scarring Drug 8/26/2016
Pivotal Study Results Published In The New England Journal of Medicine Confirm Safety And Efficacy Of InSightec's Exablate Neuro System For The Treatment Of Essential Tremor 8/25/2016
Prima Biomed (PRR.AX): Operational Update 8/19/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
ScarX Therapeutics Announces Approval For Trial Of First Clinically-Promising Scar Reduction Cream 8/18/2016
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016
Karos Pharmaceuticals Announces Major Milestone Events 8/18/2016
New First-in-Pediatrics Trial At Children's Hospital Los Angeles To Test AstraZeneca Pharmaceuticals LP (AZN)'s Durvalumab For Certain Cancers 8/18/2016
Audentes (BOLD) Announces First Patient Enrolled In The INCEPTUS Clinical Assessment Study Of XLMTM 8/17/2016
Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph 8/17/2016
ARMO BioSciences Announces Publication Of AM0010 Clinical Data In Advanced Solid Tumor Patients In Journal Of Clinical Oncology (JCO) 8/16/2016
Regen BioPharma Receives New Preliminary HemaXellerate Clinical Data On Bone Marrow Suppression From Pan Am Cancer Treatment Center 8/16/2016
AbGenomics Corporation Announces FDA Acceptance To Commence Phase I Clinical Trial Of Abgn-107 ADC Candidate For Pancreatic, Gastric, And Colorectal Cancer Treatments 8/15/2016
FDA: Toxicity Seen In Fatal French Study Does Not Extend To Other FAAH Inhibitors 8/15/2016
Sun BioPharma Announces Completion Of The Second Patient Cohort And Starts Recruitment Of Third Cohort Patients In The Dose Escalation Phase 1 Study Of SBP101 For Pancreatic Cancer 8/15/2016
Results From Phase 1 Trials With Ligand (LGND)’s LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism 8/15/2016
Tivorsan Pharmaceuticals, Inc. Granted FDA Orphan Drug Designation For Human Recombinant Biglycan In The Treatment Of Duchenne Muscular Dystrophy 8/15/2016
Fractyl’s Revita DMR Significantly Improves Hyperglycemia In Type 2 Diabetes Patients 8/12/2016
Vigilant Biosciences Awarded Phase I SBIR Grant For Next Generation Oral Cancer Diagnostic System 8/11/2016
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema 8/11/2016
SAb Biotherapeutics Release: Phase I Clinical Trials Underway For First MERS Treatment 8/11/2016
Biocryst (BCRX) Announces Initiation Of The Apex-1 Clinical Trial Of BCX7353 For Hereditary Angioedema 8/11/2016
Inovio Pharma (INO) Expands Positive Phase I Ebola Vaccine Trial To Identify Most Optimal Immunization Regimen 8/11/2016
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016
RetroSense Therapeutics Completes Low Dose Cohort In Clinical Trial Of Novel Gene Therapy Application Of Optogenetics 8/10/2016
TARIS Biomedical Launches Second Phase 1b Clinical Trial Of TAR-200 (Gemris) In Patients With Bladder Cancer 8/10/2016
Amphivena Therapeutics Announces Acceptance Of Investigational New Drug (IND) Application For AMV564 And Planned Phase 1 Trial Initiation 8/10/2016
Novartis AG (NVS)'s New Asthma Drug Hailed a Game-Changer After Success in Small Trial 8/9/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
Pfenex (PFNX) Announces Positive Anthrax Vaccine Study Results 8/8/2016
San Diego’s Pfenex (PFNX) Regains Full Rights to PF582 and Announces Phase I/II Results 8/8/2016
Vaxart Challenges Takeda (TKPYY) with Oral Norovirus Vaccine 8/8/2016
Intec Pharma To Pursue Development Of Accordion Pill For Cannabinoid Therapies 8/4/2016
Evotec AG (EVTG.F) Achieves Clinical Development Milestone As Part Of Its Multi-Target Alliance With Bayer (BAY) In Endometriosis 8/4/2016
AmpliPhi Bio (APHB) Completes Enrollment Of Its Investigational Phage Therapy Trial Targeting Staphylococcus Aureus 8/3/2016
ColonaryConcepts Initiates Phase I Study Of New Approach To Treating Chronic Constipation 8/3/2016
ContraVir Reports Positive Data From Phase 1b Study Of CMX157 8/2/2016
Vaxart Initiates Clinical Development Of First Oral Norovirus Vaccine 8/2/2016
EyeGate Pharma Announces Positive Top-Line Data From Phase Ib/IIa Clinical Trial Of EGP-437 For Treatment Of Post-Operative Inflammation And Pain In Cataract Surgery Patients 8/1/2016
Asterias Biotherapeutics To Report Second Quarter Results On August 15, 2016 8/1/2016
TetraPhase (TTPH) Initiates Phase I Clinical Trial For TP-6076, A Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria 8/1/2016
Autifony Therapeutics Successfully Completes Phase I Study Of AUT00206, A First-In-Class Kv3 Modulator For Schizophrenia 8/1/2016
The Results Of Phase I Clinical Trial Of The Araclon Biotech Alzheimer's Vaccine Support Its Continuation 8/1/2016
TRACT Therapeutics Presents Follow-Up Phase I Clinical Data In Kidney Transplant Recipients At The American Transplant Congress 2016 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
BioMarin (BMRN)'s Gene Therapy Yields Dramatic Results in Early Stage Hemophilia Study 7/28/2016
Protagonist Therapeutics Receives SBIR Funding For The Development Of Injectable Hepcidin Mimetics For Treatment Of Iron Overload Disorders 7/28/2016
Fibrocell (FCSC) Announces First Subjects Enrolled In Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 7/28/2016
uniQure (QURE) Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
Corium International, Inc. Presents Full Clinical Results From Phase 1 Pharmacokinetic Study Of Once-Weekly Corplex Donepezil Transdermal System 7/28/2016
Regulus (RGLS) Provides Update On Clinical Hold Of RG-101 7/28/2016
Adaptimmune (ADAP) Receives Access To Priority Medicines (PRIME) Regulatory Support For Its SPEAR T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma 7/28/2016
Agenus (AGEN) Reports Second Quarter 2016 Financial Results And Operational Progress 7/28/2016
Genelux Initiates Two Clinical Trials Of GL-ONC1 In Ovarian Cancer And Solid Organ Cancers With Leading Oncology Institutions 7/28/2016
Stemedica Cell Technologies, Inc. Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer's Disease 7/27/2016
Karyopharm (KPTI) Announces Phase Ib Selinexor Sarcoma Data Published In Journal Of Clinical Oncology 7/27/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
Seattle Genetics (SGEN) Reports Second Quarter 2016 Financial Results 7/27/2016
Bavarian Nordic (BAVA.CO) Announces Initiation Of NIH Sponsored Phase 1 Trial Of MVA-BN-based Yellow Fever Vaccine 7/27/2016
Flugen, Inc. Initiates A Phase I Clinical Trial Of The Redeeflu Universal Influenza Vaccine In Healthy Subjects 7/27/2016
Symcel Secures Phase I Horizon 2020 Grant As The Company Plans For Full Scale Commercialisation Of calScreener – The World’s First Multi Channel Calorimetry System For Antimicrobial Susceptibility Testing 7/27/2016
Adaptimmune (ADAP) Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma 7/26/2016
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016
Janssen Biotech (JNJ) Announces Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Immuno-Oncology Combination In Lung Cancer 7/26/2016
Inovio Pharma (INO) Doses First Subject In Zika Vaccine Clinical Trial 7/26/2016
Advaxis (ADXS) Release: Phase I/II Combination Trial Of AXAL And Durvalumab Completes Second Dose-Escalation Cohort 7/26/2016
CANBridge Life Sciences’s CAN-008 Approved For Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan 7/26/2016
GamaMabs Pharma SA Starts Phase Ia/Ib Study Of First-In-Class Monoclonal Antibody GM102 In Advanced Gynecological Cancer 7/26/2016
Opthea To Host Conference Call Providing Update On Phase 1 Wet AMD Clinical Trial With OPT-302 7/26/2016
FDA Lifts Clinical Hold on GenVec (GNVC)'s Hearing Loss Candidate 7/25/2016
Guardant Health Collaborates With OncoMed (OMED) On Anti-RSPO3 Clinical Trial 7/25/2016
Halozyme (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 7/25/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Reports Progress In Two Lead Cancer Immunotherapy Programs 7/25/2016
NewLink Genetics (NLNK) Announces Merck & Co. (MRK) Receives Breakthrough Therapy Designation From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine (V920) 7/25/2016
First Subject Treated In Zosano (ZSAN)'s Pivotal Efficacy Trial For M207 Patch For Acute Migraine 7/25/2016
KaloBios (KBIO) Announces First Patient Dosed In Phase I Study Of Lenzilumab For The Treatment Of Chronic Myelomonocytic Leukemia 7/25/2016
Alnylam (ALNY) To Report New Clinical Results With Fitusiran At The World Federation of Hemophilia 2016 World Congress 7/25/2016
FDA Grants QIDP And Fast Track Designations To MCB3837, Morphochem AG’s Novel Intravenous Antibacterial To Treat C. Difficile Infections 7/25/2016
Alnylam (ALNY) Announces New Positive Interim Phase I Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational Rnai Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders 7/25/2016
FDA Calls Pfizer (PFE), Spark Therapeutics (ONCE)'s Hemophilia B Drug a Breakthrough 7/22/2016
ViaCyte Awarded New CIRM Grant To Develop PEC-Direct For High-Risk Type 1 Diabetes 7/22/2016
Resverlogix (RVX.TO) Announces Dosing Of First Two Patients In Expanded Renal And Orphan Programs 7/22/2016
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely To The Skin 7/21/2016
TRANSGENE (ENX:TNG) To Continue Phase I/Ib Study With TG1050 In Chronic Hepatitis B Patients On The Recommendation Of The Trial’s Safety Review Committee 7/21/2016
AveXis' Spine Therapy Wins Breakthrough Tag From the FDA 7/20/2016
Pulmatrix And Mylan (MYL) Report Positive Pharmacokinetic Bioavailability Data In Pilot Study Of PUR0200 In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/19/2016
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis 7/19/2016
Cytori Therapeutics (CYTX) Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration 7/19/2016
Navidea (NAVB) Receives IRB Approval For Its Lymphoseek Rheumatoid Arthritis Clinical Trial Protocol 7/19/2016
Updated Data For Epacadostat, Incyte (INCY)’s Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016 7/19/2016
Symcel Release: Initial €50,000 Phase 1 Grant Will Fund Full Feasibility Study 7/18/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research 7/18/2016
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths 7/18/2016
MabVax Therapeutics Initiates Patient Enrollment In A Phase I Trial For A New Diagnostic Imaging Product For Pancreatic Cancer 7/18/2016
Champions Oncology, Inc. (CSBR) Successfully Delivers First AML Study 7/18/2016
Bexion Pharmaceuticals Receives FDA Clearance For The First Clinical Trial Using BXQ-350 To Dose Patients With Cancer 7/18/2016
With Little Fanfare, Biogen (BIIB) Sneaks Lupus Drug Into a Phase I Trial 7/15/2016
Armagen Presents Data From First Cohort Of Phase 1/2a Of AGT-182 For Treatment Of Hunter Syndrome 7/15/2016
ProtoKinetix Inc. (PKTX.OB)’ 2nd Quarter Scientific Update 7/14/2016
Alexion (ALXN) Presents New SBC-103 (rhNAGLU Enzyme) Phase I/II Data On Brain MRI And Neurocognitive Assessments In Patients With Mucopolysaccharidosis IIIB (MPS IIIB) 7/14/2016
Celyad Successfully Completes Safety Follow-Up Of The First Patient At The Fourth Dose Level In The NKR-2 Phase I Trial 7/14/2016
Oncodesign SA Announces The Launch Of Its First Clinical Study On A Radiotracer In Patients With Non-Small Cell Lung Cancer 7/13/2016
Mologen (MOLGF.PK): First Patient Recruited In Combination Study With Lefitolimod And Yervoy 7/13/2016
Oncternal Therapeutics' TK216 Receives Orphan Drug Designation For The Treatment Of Ewing Sarcoma, A Rare Pediatric Cancer 7/13/2016
Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925 7/13/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016
TARIS Biomedical Initiates Phase Ib Clinical Trial Of TAR-200 (Gemris™) In Patients With Muscle-Invasive Bladder Cancer 7/13/2016
3 Nauseating Clinical Trial Flops of 2016 So Far 7/12/2016
Asterias Biotherapeutics Completes Enrollment And Dosing For The First Efficacy Cohort Of The AST-OPC1 Scistar Phase 1/2a Clinical Trial In Complete Cervical Spinal Cord Injury 7/12/2016
Celldex (CLDX) Initiates Phase I/II Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma 7/12/2016
Akari Therapeutics Receives Positive Opinion For Orphan Drug Designation For Coversin In The European Union For Treatment Of Paroxysmal Nocturnal Hemoglobinuria 7/12/2016
VAXIMM Initiates Phase 1 Translational Study In Glioblastoma With Oral T-Cell Immunotherapy, VXM01 7/12/2016
uniQure (QURE) Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress 7/11/2016
Zavante Therapeutics Enrolls First Patient In The ZEUS Study For ZTI-01 For The Treatment Of Complicated Urinary Tract Infections 7/11/2016
Acceleron Pharma Announces ACE-083 Phase 1 Results At The 14th International Congress On Neuromuscular Diseases 7/8/2016
China's BeiGene (BGNE) Starts Combination Trial For Two Novel Cancer Drugs 7/7/2016
Seres Therapeutics Announces Initiation Of A Phase 1b Clinical Trial Of SER-262 For Primary Clostridium difficile Infection 7/7/2016
Scancell (SCNLF) Delays Melanoma Trial 9 to 12 Months to Whip Up New Batch of Cancer Vaccine 7/7/2016
Nanobiotix Reports Successful Results From Phase I/II Trial Of NBTXR3 In Head & Neck Cancer 7/7/2016
Minoryx Therapeutics Initiates Phase 1 Clinical Trial Of MIN-102 7/6/2016
AnaptysBio Initiates Multiple Ascending Dose Cohorts In ANB020 Phase 1 Clinical Trial 7/6/2016
Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
Heptares Anounces Initiation Of Phase 1 Clinical Study With Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca PLC (AZN) 7/6/2016
miRagen To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 7/6/2016
Lysogene Begins Multi-National Observational Study As It Prepares To Initiate Pivotal Clinical Trial For The Treatment Of Sanfilippo Type A 7/6/2016
This Year’s Top 10 Disappointing Clinical Trials—So Far! 7/6/2016
Regulus (RGLS) To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference 7/5/2016
Leap Therapeutics Presents Positive Data From Clinical Study Of DKN-01 In Combination With Paclitaxel In Esophageal Cancer 6/30/2016
First-In-Human Study Of Immbio's Novel Pneumococcal Vaccine Pnubiovax Shows Vaccine To Be Safe And Immunogenic 6/30/2016
Cytune Pharma SAS Secures EUR 6M In Financing To Advance Lead Immuno-Oncology Program To Phase I 6/30/2016
First-Ever CRISPR Trial Points to Looming Problems 6/30/2016
PsiOxus Gets Upfront $10 Million, Ties Immuno-Oncology Clinical Pact With Bristol-Myers Squibb (BMY) 6/30/2016
Symphogen Advances Sym015 Into Clinical Development Using Selexis SA SGEs (Selexis Genetic Elements) 6/29/2016
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease 6/29/2016
Janssen Pharmaceutical Companies Release: Ibrutinib (IMBRUVICA) Granted Breakthrough Therapy Designation By FDA For The Development Of A Treatment For Chronic Graft-Versus-Host Disease (cGVHD) 6/29/2016
Cascadian Therapeutics (ONTY) Receives ONT-380 Fast Track Designation From FDA For The Treatment Of Advanced HER2+ Metastatic Breast Cancer 6/29/2016
Actinium Pharmaceuticals, Inc. (ATNM.OB) Initiates Pivotal Phase 3 SIERRA Trial 6/29/2016
Acceleron Pharma Announces Presentation Of ACE-083 Phase 1 Healthy Volunteer Data At The 14th International Congress On Neuromuscular Disease 6/29/2016
Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent BIS-001 At Eilat Conference On New Antiepileptic Drugs 6/28/2016
Neuromax Announces Start Phase 1 Clinical Trial Of AQU-005 For The Treatment Of Neuropathic Pain 6/28/2016
Vaxart Initiates Clinical Development Of First Oral RSV Vaccine 6/28/2016
SanBio, Inc. Presents Interim Results Of Chronic Stroke Phase I/IIa Clinical Trial At International Society Of Stem Cell Research Annual Meeting 6/24/2016
MRI' Clearpoint Neuro Navigation Technology Highlighted In Voyager Therapeutics (VYGR) Interim Parkinson’s Disease Gene Therapy Study Results 6/24/2016
City of Hope, Novonco Announce First-In-Human Clinical Trial For COH29 6/24/2016
Roche (RHHBY) CEO 'Sleeping Much Better' Following Positive News About Three New Drugs 6/23/2016
Apellis Pharma Announces Positive Results From Phase 1 Clinical Trials Of APL-2, A C3 Complement Inhibitor 6/23/2016
Retrophin (RTRX) Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson’s Disease And Movement Disorders 6/23/2016
Cellectar Biosciences  (CLRB) Announces Results Of NCI-Sponsored Study Of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer 6/23/2016
CytoSorbents Awarded $150,000 Phase I STTR Contract For Universal Plasma Development 6/22/2016
ViaCyte To Present At ISSCR 2016 Annual Meeting 6/22/2016
Voyager Therapeutics (VYGR) Announces Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson’s Disease 6/22/2016
Agenus (AGEN) Announces Commencement Of Phase I/II Clinical Trial Of Anti-GITR Checkpoint Antibody INCAGN1876 In Patients With Solid Tumors 6/22/2016
Inovio Pharma (INO): The Surprising Leader in the Zika Vaccine Race 6/21/2016
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016
Global Blood Therapeutics (GBT) Announces Pricing Of Public Offering Of Common Stock 6/21/2016
ProQR Therapeutics B.V. (PRQR) To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC 6/21/2016
Seres Therapeutics Presents New Data At American Society for Microbiology Microbe 2016, Including Characterization Of SER-262, The Rationally-Designed, Fermented Microbiome Therapeutic Candidate For Primary Clostridium Difficile Infection 6/21/2016
Cellectis (ALCLS) Announces First Patient Treated In Phase 1 Trial Of UCART19 In Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 6/21/2016
Asterias Biotherapeutics Announces Oral Presentation And Participation In Panel Discussion At The ISSCR 14th Annual Meeting 6/21/2016
Gilead (GILD) Presents Preliminary Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV 6/20/2016
Unum Announces Active Investigational New Drug (IND) Application For ACTR087 In Patients With Relapsed/Refractory B-Cell Lymphoma 6/20/2016
Enanta Pharmaceuticals, Inc. Initiates Proof-Of-Concept Study With Pan-Genotypic Cyclophilin Inhibitor EDP-494 In Patients With Genotype 1 Or Genotype 3 Chronic Hepatitis C Virus 6/20/2016
Fate Therapeutics (FATE) Announces FDA Fast Track Designation For Protmune 6/20/2016
Poxel SAS Announces Positive Results From the First Stage Of The Ongoing PXL770 Phase 1 Trial 6/20/2016
Oncternal Therapeutics Receives Fast Track Designation For TK216 In Relapsed Or Refractory Ewing Sarcoma 6/20/2016
Juniper Pharma (JNP) Announces Phase 1 Studies Of COL-1077 Lidocaine Vaginal Gel Published In Peer Reviewed Scientific Journal 6/17/2016
Scancell (SCNLF) Suspends Dosing in Melanoma Trial Due to Quality Issues 6/17/2016
Zenith Announces Dosing Of First Patient In Phase 1 Clinical Trial And Corporate Update Webcast Details 6/16/2016
Pfizer (PFE) Head of R&D Talks Strategy on How Pharma Chooses Compounds to Bet A Billion Dollars On 6/16/2016
Capricor Therapeutics, Inc. Reports Positive 12-Month Data From The DYNAMIC Clinical Trial 6/16/2016
Senhwa Announces Enrollment Of First Patient In Phase I/II CX-5461 Trial In Triple Negative Breast Cancer 6/15/2016
Cascadian Therapeutics (ONTY) Reports Topline ONT-380 "Triplet" Data and Outlines Key Development Strategies 6/14/2016
MabVax Therapeutics Launches Second Investigational Site With Sarah Cannon Research Institute In Ongoing Phase I Clinical Trial To Evaluate New Treatment For Pancreatic Cancer 6/14/2016
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity 6/13/2016
Fibrocell (FCSC) Announces Initiation Of Patient Recruitment In Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 6/13/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Receives FDA Fast Track Designation For Treatment Of Acute Myeloid Leukemia 6/13/2016
True North Therapeutics ’s Lead Product Candidate, TNT009, Demonstrates High Response Rates And Rapid Onset Of Action In Interim Clinical Data In Patients With Cold Agglutinin Disease (CAD) 6/13/2016
Eleven Bio (EBIO) Announces Investigational New Drug Application Submission To Initiate Clinical Trials Of EBI-031 For Ocular Diseases 6/13/2016
BioTime (BTX)’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD 6/13/2016
True North Therapeutics To Present Clinical Data In Patients With Cold Agglutinin Disease (CAD) For Lead Product Candidate TNT009 6/13/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference 6/13/2016
Prothena (PRTA) Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases 6/10/2016
Achillion (ACHN) Presents Interim Phase I Results For ACH-4471, A Novel Orally-Administered Factor D Inhibitor, At The 21st Congress Of The European Hematology Association 6/10/2016
Ra Pharma Presents Clinical Data On Complement C5 Inhibitor RA101495 At The 21st Congress Of The European Hematology Association 6/10/2016
Alexion (ALXN) Release: Late-Breaking Data Presented At European Hematology Association: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase I/II Study Exhibit Rapid And Sustained Reductions In LDH 6/10/2016
GlycoMimetics, Inc. (GLYC)’ GMI-1271 Yields High Remission Rates And Favorable Tolerability In Phase I Portion Of Phase I/II Clinical Trial For AML 6/10/2016
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity 6/10/2016
Concert Pharmaceuticals, Inc. (CNCE) Presents CTP-656 Phase I Results At European Cystic Fibrosis Conference 6/10/2016
Global Blood Therapeutics (GBT) Stock Surges on Promising Sickle Cell Drug Results 6/10/2016
Cerulean Pharma Inc. (CERU) Announces Manuscript Published in Annals of Oncology 6/9/2016
Alnylam (ALNY) Initiates Phase I Clinical Trial For ALN-Ttrsc02, An Investigational Rnai Therapeutic For The Treatment Of TTR-Mediated Amyloidosis 6/9/2016
New Data Presented At The Annual European Congress Of Rheumatology (EULAR 2016) Demonstrate Safety And Efficacy Of Biogen (BIIB)’s Anti-TNF Biosimilars Portfolio 6/9/2016



//-->